Xeophin launched inMelbourne Australia in 2014 as a vehicle for founders Molloy and Neilson to commercialise their extensive understanding of large payload, viral vector based, gene therapies, and to advance their knowledge gathered through years of development at Sementis Ltd.
Xeophin is leading the way with the application of cutting edge Gene Therapy built around large payload, replication incompetent, viral vectors based on the Pox family of viruses, and designed for commercial and scalable manufacture in genetically engineered, suspension rescue cell lines, which have been altered with the careful application of gene editing techniques and rapid prototyping.
Using our Therapeutic Gene Discovery Platform, PROScreen™, Xeophin will be able to undertake rapid identification and prototyping of virally derived therapeutic targets that have been identified to have a potentially significant clinical outcome in autoimmune and inflammatory conditions for diseases that are considered both rare and unmet, alongside some of the largest grossing markets. The outputs from PROScreen™ provide a solid foundation, with proof of concept in-vitro in whole human blood, along with a clear understanding of the method of action.
To date, all Intellectual Property has been developed in-house by founders Molloy & Neilson, with Xeophin’s first Patent focusing on a virally derived protein that binds to, and inhibits both TNF-a and TNFR1/R2 in an MHC Class 1 fashion to treat conditions such as Rheumatoid Arthritis, Osteoarthritis, Psoriasis, Uveitis, Dry Eye Syndrome, Pemphigus Vulgaris, Pyoderma Gangrenosum, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Oral Mucositis. This Intellectual Property is the cornerstone of our greater patent family, incorporating our Gene Therapy product, and will prove the technology along with providing the in-house technical know-how to rapidly produce new and compelling clinical Gene Therapy targets.